Companies › Suzhou Junjing BioSciences
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WJ01024 tablets | – | Phase 1 | Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly | Oct 2027 |
| JS111 capsules (AP-L1898) EGFR inhibitor | EGFR | Phase 1 | NSCLC | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06909136 | WJ01024 tablets | Phase 1 | Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly | Oncology | Oct 2027 |
| NCT06940401 | JS111 capsules (AP-L1898) | Phase 1 | NSCLC | Oncology | Jul 2028 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.